Mr. Powell joined Medivation as senior vice president, general counsel and corporate secretary in May 2015. He brings to Medivation more than 25 years of leadership experience in the life sciences, most recently as executive vice president, general counsel and corporate secretary of InterMune, where he helped the company prepare for the U.S. approval and launch of Esbriet® (pirfenidone) as a treatment for idiopathic pulmonary fibrosis and played a leadership role in InterMune’s acquisition by Swiss drug maker Roche for more than $8 billion. Early in his career, Mr. Powell held positions of increasing responsibility for nearly 15 years at the multi-national healthcare company Baxter, where he was instrumental in a series of transactions that established Baxter throughout Asia; Mr. Powell led the global law practice at Baxter Bioscience. Subsequently, he was part of the senior team that repositioned Collagenex Pharmaceuticals as a leader in dermatology. Mr. Powell then served as senior vice president and general counsel at ImClone Systems, where he helped the company grow before playing a key role in a successful process that resulted in a sale to Eli Lilly. Immediately prior to joining InterMune, he was executive vice president, general counsel and secretary at Cornerstone Therapeutics through its successful sale to Chiesi Farmaceutici S.p.A.

 Cornerstone Therapeutics